Oxford, GSK in cancer deal

Oxford BioTherapeutics Ltd. (Abingdon, U.K.) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will partner to develop antibodies to treat primary, metastatic and recurring forms of cancer. GSK will be responsible for discovering, developing and commercializing mAbs against Oxford targets. Oxford (formerly Oxford Genome Sciences Ltd.) will develop one mAb through to clinical proof of concept, after which the pharma will have an exclusive option to license exclusive, worldwide rights to the mAb and assume further development and commercialization. ...